Switching Infliximab from IV to Subcutaneous for Crohn's
Part of Digestive system clinical trials.
This study tests whether switching from an IV infliximab to a subcutaneous (under-the-skin) version is safe and works well for people with moderate to severe Crohn's disease. It's for people who have never used a biologic and need a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have moderate to severe Crohn's disease that affects your small intestine and colon (ileocolonic Crohn's)
- You have never taken a biologic medicine for Crohn's before
- You have tried other treatments (like steroids or immune suppressants) and they didn't work well enough or you couldn't take them
- You do not have an active infection like tuberculosis, a serious abscess, or certain other infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adjusting the dose of infliximab (a biologic medicine given by IV) based on drug levels in your blood works better for treating draining fistulas caused by Crohn's disease. It is for people who have not tried other biologics and whose fistulas have not healed with usual treatments.
This study tests if switching from a high-dose infliximab IV infusion to a daily or weekly injection under the skin works just as well. It is for people with inflammatory bowel disease who are already stable on IV infliximab.
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This trial uses a computer model to study how the body processes infliximab (a medicine that reduces inflammation) in people with Crohn's disease or ulcerative colitis. It aims to find the best dose to help control symptoms.
This study looks at how well a subcutaneous (under-the-skin) form of infliximab works for people with acute severe ulcerative colitis, after they've had initial treatment with the intravenous (IV) form. It may help doctors understand if switching to injections is a good option.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.